New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide
Source: PR Newswire
Caris Life Sciences® a leading TechBio company, has announced the launch of its new national campaign titled, “Math,” featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris’ groundbreaking multi-cancer early detection (MCED) blood test.
At the heart of the “Math” campaign is a simple but powerful promise: when cancer is found earlier, patients may have more treatment options and better outcomes. Caris Detect is designed to help individuals gain earlier insight into their health through advanced blood-based testing powered by molecular science and artificial intelligence. By providing information that may help identify cancer-associated signals before symptoms appear, Caris Detect empowers people to take a more proactive role in their healthcare.
Caris Detect is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals in the bloodstream. The test combines ultra-deep Whole Genome Sequencing (WGS), Whole Transcriptome Sequencing (WTS), and advanced artificial intelligence to analyze a broad range of biological signals associated with cancer. Caris Detect analyzes the entire genome and transcriptome to provide a more comprehensive view of molecular patterns associated with cancer compared to approaches that evaluate only a limited subset of biomarkers.
“Early detection remains one of the greatest opportunities to save lives-,” said David Dean Halbert, Founder, Chairman and Chief Executive Officer of Caris Life Sciences. “With Caris Detect, we are applying decades of leadership in molecular science and artificial intelligence to help create a future where cancer may be detected earlier, when treatment options are broader and survival rates are improved. Kevin’s authenticity, credibility, and ability to connect with people across generations will inspire more people to take a proactive approach to their health.”
Costner partnered with Caris because of the company’s mission to transform healthcare through earlier detection and advanced molecular science. The campaign highlights a simple belief: when people have access to better information earlier, they can make more informed healthcare decisions.
“Cancer has touched so many families, including people I know and care about,” said Kevin Costner, award-winning actor, director and producer. “What attracted me to a partnership with Caris was their commitment to helping people get information earlier and its belief that science and technology can help change what’s possible. If a conversation about early detection encourages even one person to become more proactive about their health, that’s meaningful. Get the test.”
Individuals interested in learning more about Caris Detect may visit CarisDetect.com.
About Caris Detect™
Caris Detect™ is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence. The test analyzes a broad range of molecular information to help support earlier detection and more informed healthcare conversations. Caris Detect is designed to complement routine cancer screening and is now available nationwide.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
